What is Zacks Research's Estimate for TEVA Q3 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a report issued on Monday, November 4th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.67 per share for the quarter, up from their previous estimate of $0.66. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' FY2025 earnings at $2.55 EPS and Q2 2026 earnings at $0.61 EPS.

Several other analysts also recently commented on TEVA. Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Barclays upped their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $1.34 on Wednesday, hitting $17.43. The stock had a trading volume of 18,205,241 shares, compared to its average volume of 9,296,835. The company's 50 day moving average price is $18.00 and its 200 day moving average price is $17.06. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The stock has a market cap of $19.75 billion, a price-to-earnings ratio of -44.69, a P/E/G ratio of 1.34 and a beta of 0.87. Teva Pharmaceutical Industries has a 52-week low of $8.55 and a 52-week high of $19.31.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the company. QRG Capital Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 53.7% in the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company's stock worth $2,028,000 after acquiring an additional 50,247 shares during the period. Capital Wealth Planning LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $2,169,000. SG Americas Securities LLC grew its holdings in Teva Pharmaceutical Industries by 12.0% during the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company's stock valued at $8,613,000 after buying an additional 65,529 shares during the last quarter. Coronation Fund Managers Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $1,334,000. Finally, Point72 Asset Management L.P. grew its holdings in Teva Pharmaceutical Industries by 38.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company's stock valued at $21,437,000 after buying an additional 363,217 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.